|
DCF -Bewertung von Adaptimmune Therapeutics plc (ADAP)
GB | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Adaptimmune Therapeutics plc (ADAP) Bundle
Entdecken Sie das finanzielle Potenzial von Adaptimmune Therapeutics Plc (ADAP) mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Prognosen für Wachstum, Margen und Ausgaben ein, um den inneren Wert von Adaptimmune zu berechnen und Ihre Anlagestrategie zu verfeinern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1 | 4.0 | 6.1 | 27.1 | 60.3 | 113.8 | 215.0 | 405.9 | 766.6 | 1,447.6 |
| Revenue Growth, % | 0 | 252.76 | 55.36 | 341.5 | 122.05 | 88.84 | 88.84 | 88.84 | 88.84 | 88.84 |
| EBITDA | -131.8 | -125.8 | -155.7 | -155.6 | -128.2 | -113.8 | -215.0 | -405.9 | -766.6 | -1,447.6 |
| EBITDA, % | -11743.32 | -3178.65 | -2531.78 | -573.13 | -212.67 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 8.0 | 7.7 | 6.6 | 6.1 | 9.8 | 77.1 | 145.6 | 275.0 | 519.2 | 980.5 |
| Depreciation, % | 716.86 | 193.36 | 106.79 | 22.36 | 16.32 | 67.74 | 67.74 | 67.74 | 67.74 | 67.74 |
| EBIT | -139.8 | -133.5 | -162.2 | -161.7 | -138.0 | -113.8 | -215.0 | -405.9 | -766.6 | -1,447.6 |
| EBIT, % | -12460.17 | -3372.01 | -2638.56 | -595.49 | -228.99 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 89.5 | 368.2 | 369.6 | 204.6 | 146.9 | 113.8 | 215.0 | 405.9 | 766.6 | 1,447.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 19.3 | .1 | .8 | 7.4 | 46.9 | 50.3 | 95.0 | 179.4 | 338.8 | 639.7 |
| Account Receivables, % | 1718.72 | 3.51 | 12.23 | 27.39 | 77.83 | 44.19 | 44.19 | 44.19 | 44.19 | 44.19 |
| Inventories | 1.5 | 2.1 | .7 | 1.3 | .0 | 38.6 | 72.9 | 137.6 | 259.9 | 490.9 |
| Inventories, % | 130.04 | 52.7 | 12.13 | 4.71 | 0 | 33.91 | 33.91 | 33.91 | 33.91 | 33.91 |
| Accounts Payable | 6.4 | 6.4 | 8.1 | 4.8 | 8.1 | 75.4 | 142.3 | 268.7 | 507.5 | 958.3 |
| Accounts Payable, % | 566.58 | 161.42 | 131.94 | 17.51 | 13.48 | 66.2 | 66.2 | 66.2 | 66.2 | 66.2 |
| Capital Expenditure | -3.1 | -2.9 | -8.8 | -29.7 | -4.9 | -86.9 | -164.0 | -309.7 | -584.9 | -1,104.5 |
| Capital Expenditure, % | -273.98 | -73.42 | -142.8 | -109.55 | -8.1 | -76.3 | -76.3 | -76.3 | -76.3 | -76.3 |
| Tax Rate, % | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 |
| EBITAT | -140.1 | -133.6 | -163.1 | -164.1 | -139.7 | -113.8 | -215.0 | -405.9 | -766.6 | -1,447.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -149.5 | -110.3 | -162.8 | -198.4 | -169.5 | -98.3 | -245.4 | -463.4 | -875.2 | -1,652.6 |
| WACC, % | 14.99 | 14.99 | 14.99 | 14.99 | 14.99 | 14.99 | 14.99 | 14.99 | 14.99 | 14.99 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,898.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,686 | |||||||||
| Terminal Value | -12,972 | |||||||||
| Present Terminal Value | -6,451 | |||||||||
| Enterprise Value | -8,349 | |||||||||
| Net Debt | -119 | |||||||||
| Equity Value | -8,230 | |||||||||
| Diluted Shares Outstanding, MM | 1,206 | |||||||||
| Equity Value Per Share | -6.82 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Adaptimmune Therapeutics plc’s financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Real-Life ADAP Data: Pre-filled with Adaptimmune Therapeutics' historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Develop multiple forecasting scenarios to assess various valuation outcomes.
- User-Friendly Design: Intuitive, organized, and crafted for both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Adaptimmune data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Adaptimmune’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Adaptimmune Therapeutics plc (ADAP)?
- Accuracy: Utilizes real Adaptimmune financial data for precise calculations.
- Flexibility: Allows users to easily modify and test various inputs.
- Time-Saving: Eliminates the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and precision expected by CFOs.
- User-Friendly: Intuitive design makes it accessible for users without advanced financial skills.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Adaptimmune Therapeutics plc (ADAP) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Adaptimmune Therapeutics plc (ADAP).
- Consultants: Deliver professional valuation insights on Adaptimmune Therapeutics plc (ADAP) to clients quickly and accurately.
- Business Owners: Understand how biotechnology firms like Adaptimmune Therapeutics plc (ADAP) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Adaptimmune Therapeutics plc (ADAP).
What the Template Contains
- Historical Data: Includes Adaptimmune Therapeutics plc’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Adaptimmune Therapeutics plc’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Adaptimmune Therapeutics plc’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.